Английская Википедия:Esreboxetine

Материал из Онлайн справочника
Версия от 16:05, 4 марта 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Chemical compound}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 451553392 | IUPAC_name = (2''S'')-2-[(''S'')-(2-ethoxyphenoxy)phenyl<br />methyl]morpholine | image = Esreboxetine.svg | width = 150px <!--Clinical data--> | tradename = | pregnancy_category = | legal_status = Uncontrolled | routes_of_administration = Oral admin...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Esreboxetine (developmental code names AXS-14, PNU-165442G) is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued.[1][2][3][4] It is the (S,S)-(+)-enantiomer of reboxetine and is even more selective as a norepinephrine reuptake inhibitor in comparison.[1][5]

However, recently it has been found that esreboxetine could be effective in fibromyalgia patients.[6]

References

Шаблон:Reflist

Шаблон:Stimulants Шаблон:Analgesics Шаблон:Monoamine reuptake inhibitors


Шаблон:Analgesic-stub